Evaluation of increased preoperative serum high sensitive C-reactive protein and procalcitonin levels on grade and stage of clear cell renal cell carcinoma

Clinical Nephrology

Volumn 83, Issue 4, 2015, Pages 225-230

  Hamidi, Nurullah ^a   Gökçe, Mehmet Ilker ^a   Süer, Evren ^a   Baltaci, Sümer ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Fuhrman grade; High sensitive C reactive protein (hs CRP); Procalcitonin (PCT); Renal cell cancer; Stage

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN; C-REACTIVE PROTEIN; CALCITONIN; PROTEIN PRECURSORS;

AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; KIDNEY CARCINOMA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; PARTIAL NEPHRECTOMY; PREDICTION; PREOPERATIVE EVALUATION; RECEIVER OPERATING CHARACTERISTIC; BLOOD; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PATHOLOGY; ROC CURVE;

AGED; C-REACTIVE PROTEIN; CALCITONIN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROTEIN PRECURSORS; ROC CURVE;

EID: 84940101459     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN108448     Document Type: Article

References (19)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49: 1374-1403. CrossRef PubMed
2. Kozlowski JM. Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites. Urol Clin North Am. 1994; 21: 601-624. PubMed
3. Steffens S, Köhler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk MA, Schrader AJ. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer. 2012; 12: 399. CrossRef PubMed
4. Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A, Lorusso V, Guida M. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol. 2005; 173: 52-55. CrossRef PubMed
5. Atzpodien J, Royston P, Wandert T, Reitz M; DGCIN - German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003; 88: 348-353. CrossRef PubMed
6. Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007; 61: 824-833. CrossRef PubMed
7. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007; 99: 77-80. CrossRef PubMed
8. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and Creactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol. 2006; 13: 1365-1370. CrossRef PubMed
9. Giovanella L, Verburg FA, Imperiali M, Valabrega S, Trimboli P, Ceriani L. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. Clin Chem Lab Med. 2013; 51: 1477-1481. CrossRef PubMed
10. Walter MA, Meier C, Radimerski T, Iten F, Kränzlin M, Müller-Brand J, de Groot JW, Kema IP, Links TP, Müller B. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer. 2010; 116: 31-40. PubMed
11. Sobin LH, Gospodariwicz M, Wittekind C, (eds). TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. New York: Wiley-Blackwell; 2009. p. 255-257.
12. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6: 655-663. CrossRef PubMed
13. Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol. 2009; 9: 351-369. CrossRef PubMed
14. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010; 6: 149-163. CrossRef PubMed
15. Hu Q, Gou Y, Sun C, Ding W, Xu K, Gu B, Xia G, Ding Q. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol. 2014; 32: 50.e1-8. PubMed
16. Bedke J, Chun FK, Merseburger A, Scharpf M, Kasprzyk K, Schilling D, Sievert KD, Stenzl A, Kruck S. Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative Creactive protein does not improve predictive accuracy. BJU Int. 2012; 110 (11 Pt B): E771-E777. CrossRef PubMed
17. de Martino M, Klatte T, Seemann C, Waldert M, Haitel A, Schatzl G, Remzi M, Weibl P. Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). BJU Int. 2013; 111: E348-E353. CrossRef PubMed
18. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003; 31: 1737-1741. CrossRef PubMed
19. Machens A, Lorenz K, Dralle H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. J Clin Endocrinol Metab. 2014; 99: 2986-2994. CrossRef PubMed